Recurrent Esophageal Stricture: Adding Intralesional Steroid to Dilation
A third dilation for the same recurring stricture, on top of already-optimized acid suppression, raises a real add-on question: does injecting corticosteroid directly into the stricture at the time of dilation meaningfully extend the interval before it narrows again.
Frank D., 68, has been dilated twice in the past year for the same peptic stricture, each time returning to solid food comfortably for a few months before dysphagia crept back in — a pattern that's started to shape how he plans visits with his grandchildren, timing trips around whichever side of a dilation cycle he happens to be on. He's been on maximized PPI therapy (omeprazole 40mg twice daily, confirmed adherent) throughout, and his most recent surveillance endoscopy showed active esophagitis controlled and no ongoing erosive disease — the acid side of the equation is genuinely optimized, which is exactly why the stricture keeps recurring despite it that has become the actual clinical problem, not undertreated reflux.
Intralesional triamcinolone, injected directly into the stricture at the time of dilation, works by suppressing local fibroblast activity and collagen synthesis at the exact site of scar formation — a mechanistically different intervention from anything aimed at reflux control, since it targets the fibrotic healing response itself rather than what triggers it. Ramage and colleagues' randomized, double-blind, placebo-controlled trial in recurrent peptic strictures found a real, if moderate, extension of the symptom-free interval and reduction in repeat-dilation frequency when steroid injection is added to standard dilation, though the effect size is modest enough that some practitioners reserve it for strictures that have already proven genuinely refractory — a threshold Frank, on his third recurrence despite optimized acid control, has now clearly crossed. "Moderate" has numbers behind it: Ramage's trial found only 13% of the steroid-injection group needed repeat dilation against 60% of the sham group, a real if not universally reproduced effect — enough to matter for someone timing family visits around his swallowing, without being large enough that either specialist treated it as a certain fix rather than a reasonable, evidence-supported addition. Frank was told directly that a fourth recurrence, if it happens despite today's added intervention, would be the point to consider a fundamentally different approach — a stent trial, or a more extensive surgical opinion — rather than a fourth cycle of the same dilation-alone approach that hasn't held for more than a few months at a time.
A stricture recurring despite optimized acid control
His acid control is genuinely optimized — confirmed adherence, controlled esophagitis on surveillance endoscopy — and the stricture has still recurred twice. That's exactly the refractory pattern the trial data behind intralesional triamcinolone was built around. I'd inject it at the time of this dilation rather than repeat the same approach a third time and hope for a different result.
I want to be precise about where that trial benefit has been shown most clearly — it's strongest in more complex, densely fibrotic strictures, and his is currently described as simple and short-segment. That doesn't mean the injection won't help him, but I'd want us honest that we may be applying it a step earlier than the population where its benefit is most established.
Given that the injection's downside risk here is genuinely low and the benefit, while modest in his simpler stricture type, is still real, I don't think that distinction argues against trying it now rather than waiting for a fourth recurrence.
Before we finalize either plan, I want to name something neither of you has raised: a stricture recurring despite genuinely optimized acid control is also a reasonable trigger to biopsy specifically for eosinophilic esophagitis, if that wasn't already done on this most recent scope. It can produce a similar recurrent-stricture pattern that wouldn't durably respond to dilation or steroid injection alone without treating the underlying eosinophilic process directly.
Agreed: dilation performed with intralesional triamcinolone injection at the stricture site, esophageal biopsies obtained specifically to evaluate for eosinophilic esophagitis, and PPI regimen continued unchanged. Biopsy results are pending; a positive finding would add topical steroid therapy for EoE on top of, not instead of, the current plan.